Sucampo
About Sucampo
Sucampo is a Healthcare company based in Rockville (United States) founded in 1996, and was acquired by Mallinckrodt Pharmaceuticals in December 2017. Prostone-based drugs are developed for gastrointestinal, ophthalmic, and oncology disorders. Sucampo has completed 2 acquisitions, including R-Tech Ueno and Vtesse. Sucampo offers products and services including AMITIZA, Rescula, VTS-270, and CPP-1X/sulindac. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is Mallinckrodt plc. Its competitors include Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Sucampo was founded in 1996 as a biopharmaceutical company specializing in prostones for treating gastrointestinal, ophthalmic, and oncology-related inflammatory conditions. Operations are maintained in the United States, Japan, Switzerland, and the United Kingdom. A marketed product, AMITIZA, is available, alongside a pipeline focused on lifecycle management and clinical programs in these therapeutic areas.
- Headquarters Rockville, United States
- Stage Acquired
- SectorsHealthcare
- Website sucampo.com
- Social LinkedIn X
- Acquired by Mallinckrodt Pharmaceuticals (Dec 2017)
- Legal Name Mallinckrodt Plc
- Latest Funding Round$300M (USD), Post-IPO
Dec 2016
- Investors
- Investments & AcquisitionsR-Tech Ueno
& 1 more
- Acquired byMallinckrodt Pharmaceuticals
(Dec 2017)
Products & Services of Sucampo
Sucampo offers a comprehensive portfolio of products and services, including AMITIZA, Rescula, VTS-270, and CPP-1X/sulindac.
Treats functional constipation in adults and children through commercialization.
Manages ophthalmic conditions with continued commercialization in Japan.
Targets rare diseases like Niemann-Pick Type C via research pipeline.
Addresses conditions like Familial Adenomatous Polyposis through development efforts.
Funding Insights of Sucampo
- Total Rounds 1
- Last Round Post-IPO — $300M
- First Round $300M
(Dec 2016)
All 1 funding rounds of Sucampo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $300M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Sucampo
Sucampo has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty pharmaceutical products and diagnostic imaging agents are manufactured. | 1867 | mallinckrodt.com | St. Louis, United States |
Investor details for Sucampo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sucampo
Sucampo has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include R-Tech Ueno and Vtesse.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drugs for lysosomal storage diseases like Niemann-Pick are developed. | vtessepharma.com | Gaithersburg, United States | 2014 | Apr 2017 | $200M | |
Novel drugs are developed and manufactured for various disease areas. | rtechueno.com | Tokyo, Japan | 1989 | Aug 2015 | $275M |
Complete acquisition details for Sucampo
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sucampo
6 dated milestones of Sucampo across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Sucampo is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires R-Tech Ueno.
- Funding First funding round of $300.0M.
- Acquisition Acquires Vtesse.
- Exit Acquired by Mallinckrodt Pharmaceuticals.
Competitors of Sucampo
Sucampo has 3 listed competitors in our database, 3 of them funded. They include Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. |
Detailed competitors of Sucampo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sucampo
Websites that share an audience with Sucampo (sucampo.com).
Websites whose visitors overlap most with Sucampo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
tpna.com | tpna.com | 100% | – | ||
| shionogi.com | 91% | 164.2K | #248,020 | View details | |
| noven.com | 90% | 7.2K | #3,107,578 | View details | |
| deciphera.com | 90% | 12.2K | #2,044,202 | View details | |
| synokempharma.com | 90% | 1.8K | #7,667,368 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Sucampo
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Sucampo (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sucampo
Complete news archive for Sucampo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sucampo
Sucampo was founded in 1996 and raised its 1st funding round 20 years after it was founded.
Sucampo is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Sucampo was founded in 1996 as a biopharmaceutical company specializing in prostones for treating gastrointestinal, ophthalmic, and oncology-related inflammatory conditions. Operations are maintained in the United States, Japan, Switzerland, and the United Kingdom. A marketed product, AMITIZA, is available, alongside a pipeline focused on lifecycle management and clinical programs in these therapeutic areas.
Sucampo's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Aclaris Therapeutics.
Sucampo offers AMITIZA, Rescula, VTS-270, and CPP-1X/sulindac.
Sucampo has made 2 acquisitions, including R-Tech Ueno, and Vtesse.
Sucampo has 1 investor. Key investors include Mallinckrodt Pharmaceuticals.
Sucampo operates through Mallinckrodt Plc.
Yes. Sucampo was acquired by Mallinckrodt Pharmaceuticals in December 2017.